



Epigenetic Regulation of Anti-tumor Immune Response

Guest Editor:

Dr. Qin Yan

Department of Pathology, Yale
University School of Medicine,
New Haven, CT 06510-3128, USA

Deadline for manuscript
submissions:

closed (31 January 2019)

Message from the Guest Editor

Dear Colleagues,

Evasion from immunosurveillance by cancer cells is a major cancer hallmark, and restoration of immunosurveillance has been demonstrated as an effective anti-tumor strategy. For example, immune checkpoint inhibitors have achieved remarkable responses. Recent studies showed that epigenetic aberrations contribute to downregulation of anti-tumor immune responses. Epigenetic targeting has shown promising effects by inducing robust anti-tumor immune response, alone or in combination with immune checkpoint inhibitors. This Special Issue is focused on the study of epigenetic regulators of anti-tumor immune response, as well as epigenetic-based therapeutics for cancer treatment. We will consider review, research, or method manuscripts with a broad interest in these areas.

Dr. Qin Yan
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ernesto Guccione

Icahn School of Medicine at
Mount Sinai, Hess Center for
Science and Medicine, New York,
NY 10029, USA

Message from the Editor-in-Chief

In the past years the growth of the epigenetic field has been outstanding, from here the need of a journal where to centralize all new information on the subject. The term epigenetics is now broadly used to indicate changes in gene functions that do not depend on changes in the sequence of DNA. *Epigenomes* covers all areas of DNA modification from single cell level to multicellular organism as well as the epigenetics on human pathologies and behavior.

Epigenomes (ISSN 2075-4655) is a fully peer-reviewed publication outlet with a rapid and economical route to open access publication. All articles are peer-reviewed and the editorial focus is on determining that the work is scientifically sound rather than trying to predict its future impact.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [ESCI \(Web of Science\)](#), [PMC](#), [PubMed](#), [Embase](#), [PubAg](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: CiteScore - Q2 (*Biochemistry, Genetics and Molecular Biology (miscellaneous)*)

Contact Us

Epigenomes Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/epigenomes
epigenomes@mdpi.com
[X@Epigenomes](#)